Bulk Pharmaceutical API Sources for IMITREX

Bulk Pharmaceutical API Sources for IMITREX

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-002-885-863
AKos Consulting & Solutions		AKOS015894924
Finetech Industry Limited		FT-0674779
Finetech Industry Limited		FT-0631027
Mcule		MCULE-3991948648

IMITREX Bulk API Sources

Last updated: February 19, 2026

This analysis identifies primary bulk active pharmaceutical ingredient (API) sources for Imitrex (sumatriptan succinate), a medication for acute migraine treatment. The focus is on manufacturers with established production capabilities and regulatory filings.

What is Sumatriptan Succinate?

Sumatriptan succinate is the chemical compound and API in Imitrex. It functions as a selective serotonin receptor agonist, specifically targeting 5-HT1B and 5-HT1D receptors. By constricting cranial blood vessels and inhibiting pro-inflammatory neuropeptide release, it alleviates migraine pain. The succinate salt form enhances solubility and bioavailability.

• Chemical Name: 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide succinate
• CAS Number: 103628-46-2 (Sumatriptan); 117128-40-4 (Sumatriptan Succinate)
• Molecular Formula: C14H21N3OS · C4H6O4
• Molecular Weight: 413.5 g/mol

Regulatory Landscape for API Manufacturing

The production of bulk APIs for pharmaceuticals like sumatriptan succinate is strictly regulated by health authorities worldwide. Key regulatory requirements include:

• Good Manufacturing Practices (GMP): Facilities must adhere to GMP standards to ensure consistent quality, purity, and safety of the API. This is overseen by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. A DMF contains proprietary information about the manufacturing process, facilities, and quality controls for an API. Pharmaceutical companies reference these DMFs in their drug product applications.
• Inspections: Regulatory bodies conduct periodic inspections of API manufacturing sites to verify compliance with GMP and other regulations.
• Impurity Profiling: Manufacturers must rigorously control and characterize impurities in the API to meet stringent safety standards.

Key Bulk API Suppliers for Sumatriptan Succinate

Multiple API manufacturers globally produce sumatriptan succinate. The following are prominent suppliers with documented manufacturing and regulatory presence.

Manufacturers with FDA DMF Filings

The U.S. FDA maintains a database of DMFs, providing insight into API suppliers whose products are used in approved drugs in the United States.

• Aurobindo Pharma Limited (India): Aurobindo is a significant player in the generic API market. Their facilities in India are GMP-compliant and have undergone FDA inspections. They offer sumatriptan succinate in bulk.
  • DMF Status: Active, publicly accessible information indicates DMF filings for sumatriptan succinate.
• Sun Pharmaceutical Industries Ltd. (India): Sun Pharma is one of the largest pharmaceutical companies globally and a major API producer. They manufacture a wide range of APIs, including sumatriptan succinate.
  • DMF Status: Confirmed filings for sumatriptan succinate are available through regulatory databases.
• Laurus Labs Limited (India): Laurus Labs is an established API manufacturer with a strong focus on complex chemistries. They have demonstrated capability in producing sumatriptan succinate.
  • DMF Status: Active DMFs for sumatriptan succinate are on file with the FDA.
• Dr. Reddy's Laboratories Ltd. (India): Dr. Reddy's is a leading integrated pharmaceutical company. Their API division is a significant supplier, and they produce sumatriptan succinate.
  • DMF Status: Regulatory filings indicate the availability of sumatriptan succinate DMFs from Dr. Reddy's.
• Torrent Pharmaceuticals Ltd. (India): Torrent Pharma is engaged in the manufacturing of APIs and finished dosage forms. They are a known producer of sumatriptan succinate.
  • DMF Status: Evidence suggests active DMF filings for sumatriptan succinate.

Manufacturers with EMA CEPs (Certificates of Suitability to the monographs of the European Pharmacopoeia)

The European Directorate for the Quality of Medicines & HealthCare (EDQM) issues CEPs, which are crucial for API suppliers seeking to market their products in Europe.

• Hetero Drugs Limited (India): Hetero is a vertically integrated pharmaceutical company with extensive API manufacturing capabilities. They are a significant producer of sumatriptan succinate and hold CEPs for various APIs.
  • CEP Status: Sumatriptan succinate has a granted CEP, allowing its use in European drug product applications.
• Divi's Laboratories Limited (India): Divi's is a prominent global API manufacturer known for its large-scale production and strong regulatory compliance.
  • CEP Status: Sumatriptan succinate is listed in the EDQM database with an active CEP.
• Piramal Pharma Solutions (India): Piramal offers contract development and manufacturing (CDMO) services, including API production. They have demonstrated expertise in producing sumatriptan succinate.
  • CEP Status: CEPs for sumatriptan succinate are held by Piramal, indicating compliance with European Pharmacopoeia standards.

Other Notable Global API Manufacturers

Beyond those with direct FDA DMFs or EMA CEPs readily searchable, other manufacturers operate globally and may supply sumatriptan succinate, often through partnerships or for markets with different regulatory frameworks.

• Takeda Pharmaceutical Company (Japan): While Takeda is primarily known for its finished drug products, it also has internal API manufacturing capabilities. Historically, they have been involved in sumatriptan production.
• Cipla Limited (India): Cipla is a major Indian pharmaceutical company with substantial API manufacturing operations, including capacity for various neurological agents.
• Mylan N.V. (now part of Viatris) (Global): Through its acquisitions and global network, Mylan (Viatris) has access to diverse API sources and manufacturing sites that may produce sumatriptan succinate.

Manufacturing Capacity and Quality Considerations

API manufacturers differentiate themselves based on several factors critical for pharmaceutical companies sourcing bulk ingredients:

• Scale of Production: The ability to produce large commercial volumes is essential for meeting market demand for a widely prescribed medication like Imitrex. Indian manufacturers, in particular, have invested heavily in large-scale facilities.
• Quality Control and Assurance: Robust quality management systems, including advanced analytical testing for identity, purity, and potency, are paramount. This includes control of residual solvents, heavy metals, and process-related impurities.
• Supply Chain Reliability: Consistent and uninterrupted supply is vital. Manufacturers with multiple production sites or redundant manufacturing processes offer greater supply chain security.
• Cost-Effectiveness: While quality is non-negotiable, competitive pricing is a significant factor in the generic API market.
• Environmental, Social, and Governance (ESG) Practices: Increasingly, pharmaceutical companies assess suppliers' ESG performance, including their environmental impact and labor practices.

Challenges in API Sourcing

Sourcing bulk APIs for sumatriptan succinate involves navigating several challenges:

• Regulatory Scrutiny: Increased regulatory focus on API quality and supply chain integrity means manufacturers must maintain high compliance standards.
• Geopolitical Factors: Global events can impact raw material availability and logistics, affecting production timelines and costs.
• Intellectual Property: While the patent for sumatriptan itself has long expired, patents related to specific manufacturing processes or polymorphic forms can still influence sourcing.
• Impurity Control: The identification and control of genotoxic impurities or novel impurities require sophisticated analytical capabilities and process understanding.
• Sustainability: Pressure to adopt greener chemistry and sustainable manufacturing practices is growing.

Conclusion

The global market for sumatriptan succinate bulk API is served by a number of established manufacturers, predominantly based in India, who have demonstrated strong regulatory compliance through filings with agencies like the FDA and EDQM. Aurobindo Pharma, Sun Pharma, Laurus Labs, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, Hetero Drugs, and Divi's Laboratories are key entities with documented manufacturing and regulatory presences for this API. Pharmaceutical companies should assess these suppliers based on production scale, quality control systems, supply chain reliability, cost, and adherence to evolving regulatory and ESG standards.

Key Takeaways

• Prominent bulk API suppliers for sumatriptan succinate include Aurobindo Pharma, Sun Pharmaceutical Industries, Laurus Labs, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, Hetero Drugs, and Divi's Laboratories.
• Regulatory compliance, evidenced by FDA Drug Master Files (DMFs) and European Certificates of Suitability (CEPs), is critical for API manufacturers.
• Key considerations for sourcing include production scale, quality assurance, supply chain reliability, cost-effectiveness, and ESG practices.
• The API market for sumatriptan succinate is mature, with competition driven by quality, reliability, and price.

Frequently Asked Questions

1. Which countries are the primary hubs for sumatriptan succinate API manufacturing? India is the dominant manufacturing hub for sumatriptan succinate API due to its established pharmaceutical infrastructure and large-scale production capabilities.

2. What is the typical purity standard for bulk sumatriptan succinate API? Bulk sumatriptan succinate API must meet pharmacopoeial standards (e.g., USP, EP) which typically require purity levels of 98% or higher, with strict limits on specific impurities.

3. How long does it take for a new API supplier to obtain regulatory approval for sumatriptan succinate in the U.S.? The process for a new API supplier to be accepted by a drug product manufacturer and for the DMF to be reviewed by the FDA can take several months to over a year, depending on the thoroughness of the filing and the FDA's review queue.

4. Are there any known supply chain risks associated with sumatriptan succinate API at present? While no specific large-scale shortages are currently reported, general supply chain risks exist globally, including raw material availability, transportation disruptions, and geopolitical instability, which can affect any API.

5. What are the critical quality attributes (CQAs) for sumatriptan succinate API that manufacturers must control? Critical quality attributes include identity, assay (potency), purity (related substances and residual solvents), particle size distribution, polymorphic form, and moisture content.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/drug-master-files [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia. Retrieved from https://www.edqm.eu/en/certificate-suitability-monographs-european-pharmacopoeia [3] Aurobindo Pharma Limited. (n.d.). API Portfolio. Retrieved from manufacturer's official website (specific URL varies). [4] Sun Pharmaceutical Industries Ltd. (n.d.). APIs. Retrieved from manufacturer's official website (specific URL varies). [5] Laurus Labs Limited. (n.d.). APIs. Retrieved from manufacturer's official website (specific URL varies). [6] Dr. Reddy's Laboratories Ltd. (n.d.). API. Retrieved from manufacturer's official website (specific URL varies). [7] Torrent Pharmaceuticals Ltd. (n.d.). API. Retrieved from manufacturer's official website (specific URL varies). [8] Hetero Drugs Limited. (n.d.). APIs. Retrieved from manufacturer's official website (specific URL varies). [9] Divi's Laboratories Limited. (n.d.). API. Retrieved from manufacturer's official website (specific URL varies). [10] Piramal Pharma Solutions. (n.d.). API Services. Retrieved from manufacturer's official website (specific URL varies).